NOVOS Core Clinical Trial Reveals Improvements in Cardiovascular Biomarkers Associated with Healthy Longevity

NOVOS, a longevity biotechnology company developing science-backed interventions for healthy aging, today announced results from a new randomized, double-blind, placebo-controlled human clinical trial in which researchers observed statistically significant benefits over placebo across multiple validated markers of vascular aging, measured over a six-month period.

At a time when many consumer brands describe themselves as “longevity” companies, few have evaluated their finished commercial formulation in a randomized, double-blind, placebo-controlled human trial against validated healthspan-relevant biomarkers. While much of the category relies on individual ingredient research without evaluating how those ingredients perform together in a finished formulation, this study assesses the complete commercial formula, providing first-of-its-kind human evidence of simultaneous improvements in endothelial function, arterial flexibility, and systolic blood pressure already within the normal range from a single, multi-component intervention.

Importantly, the trial was conducted in adults aged 40 and older without diagnosed cardiovascular disease, meaning improvements were observed in a generally healthy population — a setting in which physiological gains are typically more difficult to achieve and therefore particularly notable.

The study was led by researchers at the University of Surrey (UK) and evaluated the early and sustained vascular effects of the NOVOS Core multi-component nutritional intervention. The trial was registered on ClinicalTrials.gov (NCT06145087). The manuscript has been made publicly available as a preprint and is currently undergoing peer review.

Participants in the intervention group demonstrated early and sustained improvements in endothelial function, with statistically significant differences versus placebo observed during the trial and for six months thereafter. Significant between-group differences were also observed in arterial flexibility and systolic blood pressure already within the normal range compared with placebo.

The magnitude of improvement across multiple vascular aging markers is uncommon for nutritional interventions and comparable in magnitude to changes reported in separate published studies of exercise, diet, and weight loss lifestyle interventions.

“These findings suggest that targeting multiple biological mechanisms involved in vascular aging may be an effective strategy for supporting vascular function earlier in life, before disease develops,” said Professor Christian Heiss, MD, senior author of the study and Professor of Cardiovascular Medicine at the University of Surrey. “Importantly, the effects were observed without changes in lipid levels, highlighting endothelial and arterial function as distinct and modifiable components of vascular aging biology.”

Key Findings

Participants were randomized to receive either NOVOS Core or placebo. Vascular assessments were performed at baseline, shortly after the first dose, and after six months of daily supplementation.

Improved Endothelial Function (Flow-Mediated Dilation, FMD)

• +2.9% improvement observed shortly after the first dose
• Sustained improvement observed after 6 months
• No meaningful change in the placebo group

In the scientific literature, a +1% improvement in FMD is often cited as physiologically meaningful.

The magnitude of improvement observed in this study (+2.9%) is within the range reported in published studies of sustained, vigorous aerobic exercise, such as high-intensity interval training (HIIT)

Improved Arterial Flexibility (Pulse Wave Velocity)

• Participants in the intervention group demonstrated a −1.18 m/s difference in pulse wave velocity compared to placebo at 6 months.

Population studies report that pulse wave velocity typically increases by approximately +1.0 m/s per decade across adulthood.

The −1.18 m/s between-group difference observed in this trial falls within ranges reported in peer-reviewed studies of DASH and Mediterranean-style dietary interventions, and greater-than-10% weight loss programs. Based on cross-study comparisons of similar endpoints, the magnitude of change observed here exceeded ranges reported in peer-reviewed studies evaluating magnesium supplementation, omega-3 fatty acids, and nitric oxide–supporting interventions such as beetroot and dietary nitrate formulations.

Healthy Blood Pressure Support (Already Within the Normal Range)

• The study observed a systolic blood pressure difference of −6.1 mmHg between the intervention and placebo groups, despite baseline values already within the normal range.

Maintaining healthy blood pressure levels within the normal range is an important component of long-term vascular function and healthspan. These findings are consistent with evidence that NOVOS Core supports healthy blood flow and vessel structure as we age and supports arterial flexibility in adult consumers of varying ages and health conditions.

The between-group differences observed in this study fall within ranges reported in separate peer-reviewed studies of structured aerobic exercise programs and resistance training interventions. Based on cross-study comparisons using similar endpoints, the reductions observed exceeded ranges reported in separate studies evaluating dietary sodium reduction, potassium supplementation, omega-3 fatty acids, quercetin, and curcumin.

Context Within Longevity Research

Cardiovascular disease remains the leading cause of death globally and increases substantially with age. Vascular function is widely studied in aging research because it changes early in the aging process and is associated with long-term physiological function.

While individual interventions have demonstrated varying degrees of vascular benefit in independent studies, few multi-pathway nutritional interventions have demonstrated statistically significant improvements across endothelial function, arterial elasticity, and systolic blood pressure simultaneously within a single placebo-controlled human trial in a healthy population.

“This trial provides rare human evidence that a multi-pathway nutritional strategy can meaningfully influence vascular aging biology itself,” said Professor Heiss. “The magnitude and consistency of these effects across multiple vascular endpoints is unusual for a nutritional intervention in a healthy population.”

Built on Years of Aging Biology Research

NOVOS began formulating NOVOS Core in 2019 with a team of scientists from Harvard Medical School and MIT, becoming the first company to design a consumer formulation explicitly intended to address all of the biological Hallmarks of Aging simultaneously.

Prior to this randomized human trial, NOVOS conducted mechanistic cellular research, preclinical animal research evaluating lifespan-related biological pathways, and preliminary epigenetic aging analyses using DNA methylation biomarkers, each of which demonstrated favorable effects on biological markers associated with aging.

Since launch, more than 10 million doses of NOVOS Core have been sold globally.

“These results move longevity science out of theory and into measurable human biology: loss of aging-related vascular health is not inevitable, and it may be modifiable earlier than we previously believed,” said Chris Mirabile, Founder and CEO of NOVOS. “Our goal is to translate rigorous aging biology into practical, evidence-based tools that help people preserve healthspan as long as possible.”

Industry Implications

As the longevity sector expands, clinical substantiation remains rare. This randomized, double-blind, placebo-controlled trial evaluating a commercially available formulation places NOVOS Core among a small subset of longevity interventions supported by controlled human data demonstrating statistically significant effects on validated physiological biomarkers associated with aging biology.

About the Study 

The study was conducted independently by investigators at the University of Surrey and affiliated NHS institutions. NOVOS provided the study product and an unrestricted research grant but had no role in data collection. The academic authors retained full control over publication decisions.